Updated Lipoprotein(a) Genomic Risk Score and Aspirin for Primary Prevention of Cardiovascular Events

Chenglong Yu, George Thanassoulis, Rory Wolfe, John J McNeil, Andrew M Tonkin, Sotirios Tsimikas, Paul Lacaze · 2023

Read Updated Lipoprotein(a) Genomic Risk Score and Aspirin for Primary Prevention of Cardiovascular Events by Chenglong Yu, George Thanassoulis, Rory Wolfe, John J McNeil, Andrew M Tonkin, Sotirios Tsimikas, Paul Lacaze (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11198050.txt.

Description

High levels of lipoprotein(a), a fatty particle in blood, raise the risk of heart and vessel disease, and genes largely set those levels. Chenglong Yu and co-authors used data from the ASPREE trial in 2023 to ask who benefits from aspirin before any disease event. Earlier work in that trial hinted that people with high genetic risk for the particle gained most from daily aspirin.

The team tested an updated genetic risk score built from 110 variants, more than twice the old count, in over twelve thousand older adults. The aim was to sharpen which subgroup gains from aspirin enough to outweigh bleeding risk. The analysis extends earlier findings that a gene score, used in place of a blood test, can guide prevention.

Catalog record

CREATORChenglong Yu, George Thanassoulis, Rory Wolfe, John J McNeil, Andrew M Tonkin, Sotirios Tsimikas, Paul Lacaze
YEAR2023
COLLECTIONPAPERS
FORMATTXT
FILE SIZE9 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11198050

Browse the full library · About the Tower of Babel